An interventional study of POC EEG in Neurologic Findings, sponsored by Indiana University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Indiana University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 185 studies in Neurologic Manifestations with a site in United States — 24 open to participants now, 38 under way, 6 of them phase 3. Neurologic Manifestations · United States.
Among the 185 studies in Neurologic Manifestations with a site in United States, this one is the 74th largest by planned enrollment of the 136 interventional ones that give a count, is one of 9 that started in 2026, is one of 63 with no phase, reaches primary completion later than 7 of the 37 other live ones, and was the 177th registered.
427 studies on the registry are indexed under Neurologic Manifestations; 80 are open to participants now.
Browse Neurologic Manifestations studies →24 of the 185 studies in Neurologic Manifestations with a site in United States are open now. Recruiting first, the newest first:
Brian J.Gill · Sites in United States
Ages 22–65
Teleflex · Sites in United States, France, Latvia and 1 more country
Ages 18–80
Peter C. Gerszten, MD · Sites in United States
Ages 21–75 · Healthy volunteers
Children's Mercy Hospital Kansas City · Sites in United States
Ages 6 mo–17 yrs
Alexander T. Yahanda · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 59 Neurologic Manifestations studies recruiting now, 31 (53%) set no upper age limit and 15 (25%) stop at 75 or younger; 15 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
185 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 35 · Phase 3 20 · Phase 4 3
First in 1988; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 48 across 270 interventional studies indexed under Neurologic Manifestations.
Median enrollment 34 across the 136 interventional studies, 100 across the 47 observational. Of the 126 that completed or were terminated, 41 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 185 have an industry lead sponsor. The 10 most frequent:
Indiana University is the lead sponsor of 991 studies on the registry; 202 are open to participants now.
Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.
Indiana University has 1 study filed under Neurologic Manifestations — fewer than ten, so there is no comparison to draw.
17 of the studies in Neurologic Manifestations with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891443Phase 3Laboratoires TheaStudy to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) | 2027-11 |
| NCT01988883Vanderbilt University Medical CenterModafinil and Cognitive Function in POTS | 2026-12 |
| NCT07223827Indiana UniversityHandheld Point of Care Electro-Diagnostic Device | 2026-12 |
| NCT07226011Medical University of South CarolinaAccelerated High-Dose tDCS for Depression | 2026-12-28 |
| NCT07218133Alexander T. YahandaTrans-Auricular Stimulation for Postoperative Inflammation in Spine Surgery | 2027-01 |
Add all 17 to your calendar (.ics) → With an account.
Among the 185 studies in Neurologic Manifestations with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There are currently several products offering POC EEG, intended to be deployed on each patient individually and continuously. The investigators propose studying a different approach by using a migrating POC electrodiagnostic device that is deployed directly by the onsite provider and is actively used, like other POC devices, to acquire real-time diagnostic insight and facilitate immediate medical decision making. This can significantly shorten time to treatment which in several neurological and neurosurgical conditions, and thus, can significantly improve patient outcome.
The investigational POC investigational device is based on a handheld limited electrode array, complemented by various stimulation modalities such as SSEP, VEP and BAEP, and potentially other sensors. For this study, the investigators intend to use readily available industry standard stimulators and only use the proposed POC investigational device to acquire and analyze the data. The POC investigational electrodiagnostic prototype was assembled using OpenBCI8 electronic board and electrodes, based on ADS 129X chip by Texas Instruments, that was shown to provide an adequate low-cost solution for electrodiagnostic data acquisition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be evaluated using the handheld POC device to compare diagnostic data collected vs. clinical diagnostic data
Diagnostic Test: POC EEG
The PI will apply the POC investigational device dry electrodes, as well as SOC SSEP stimulator to the participant and run a standardized diagnostic testing sequence, to cover all 4 limbs, spine, and head. The device connects to a laptop via Bluetooth, and the acquired electrodiagnostic data is visualized on the screen. The PI will analyze the acquired data and determine lateralization, localization, and presumed nature of the lesion or pathology causing the patient's symptoms. The direct contact with the participant should take10-20 minutes. The inferred lateralization, localization, and nature of the presumed lesion, will be then documented, to be compared to the diagnostic insight of using SOC diagnostic methods such as CT, MRI, EEG, SSEP, etc. The participant will receive their regular SOC management and a single, brief evaluation using the POC investigational device.
Outcome 1
The diagnostic insights acquired using the POC investigation device regarding lateralization (left/right), localization (cerebral - frontal, temporal, parieto-occipital; spinal - cervical, thoracal, lumbosacral; or radicular), and presumed nature of lesion (i.e. ischemia, hemorrhage, space-occupying lesion), are significantly comparable to, and congruent with, the SOC diagnostic insight regarding same parameters (lateralization, localization and presumed etiology) acquired using SOC techniques such as MRI, 10-20 (standard ubiquity used electrode montage) EEG systems, SSEP, etc. The PI will be the only POC investigational device operator, and will be blinded to patient examination, symptoms and SOC investigation results. The PI will be blinded to all EMR data. The investigator then plans to compare the clinical insight obtained by using the POC investigational device, to SOC.
Time frame: Day 0
Outcome 2
The diagnostic insights acquired using the POC investigation device regarding localization (cerebral - frontal, temporal, parieto-occipital; spinal - cervical, thoracal, lumbosacral; or radicular),are significantly comparable to, and congruent with, the SOC diagnostic insight regarding same parameters (lateralization, localization and presumed etiology) acquired using SOC techniques such as MRI, 10-20 (standard ubiquity used electrode montage) EEG systems, SSEP, etc.
Time frame: Day 0
Outcome 3
The diagnostic insights acquired using the POC investigation device regarding the presumed nature of lesion (i.e. ischemia, hemorrhage, space-occupying lesion), are significantly comparable to, and congruent with, the SOC diagnostic insight regarding same parameters (lateralization, localization and presumed etiology) acquired using SOC techniques such as MRI, 10-20 (standard ubiquity used electrode montage) EEG systems, SSEP, etc.
Time frame: Day 0
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Of 65 non-industry interventional studies with no phase under Neurologic Manifestations, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 80. This study's planned 11 months is below that.
Counting every sponsor, half of 73 studies reached it within 37 months; a quarter within 12 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.